Q-omics provides the consensus-scored RPL17P33 profile across patient tissues and cancer cell-line models. RPL17P33 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RPL17P33 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, RPL17P33 RNA expression shows 5,802 significant pathway-activity associations, with the highest sampling consensus in SKCM. Together, these results highlight COAD, KIRC, and SKCM as cancer lineages where RPL17P33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P33 survival associations across molecular data types. RPL17P33 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P33 RNA expression–survival associations across cancer types. High RPL17P33 expression shows unfavorable associations in LUAD and HNSC, but favorable associations in COAD, CESC, ESCA and SKCM. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for RPL17P33 RNA expression.
This table summarizes RPL17P33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P33 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, HNSC and LIHC. The KIRC box plot shows higher RPL17P33 RNA expression in tumor versus normal tissue (log2 FC = +0.055, t-test p = .005).
This table shows molecular features associated with RPL17P33 in patient tissues and cancer cell lines. In patient samples, RPL17P33 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
